Local Institution - 0004
ABB, Buenos Aires F.D., Argentina
11 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Solid Tumors
Bristol-Myers Squibb260 enrolled57 locationsNCT07492680
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb500 enrolled186 locationsNCT07100080
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Schizophrenia
Bristol-Myers Squibb300 enrolled18 locationsNCT07101094
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled274 locationsNCT07361510
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled161 locationsNCT07221149
Recruiting
Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Phase 1Phase 2
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Advanced Solid Tumors
Bristol-Myers Squibb360 enrolled6 locationsNCT06730750
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled22 locationsNCT06947941
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled116 locationsNCT06976216
Recruiting
Phase 1
A Phase 1 Study of Navlimetostat Tablet Formulations
Healthy Participants
Bristol-Myers Squibb64 enrolled4 locationsNCT07544628
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bipolar DisorderMania
Bristol-Myers Squibb424 enrolled104 locationsNCT07140913
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Bristol-Myers Squibb1,500 enrolled52 locationsNCT07379827
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company92 enrolled56 locationsNCT07335562
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Alzheimer DiseaseAgitation
Celgene120 enrolled53 locationsNCT06808984
Recruiting
Phase 4
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb50 enrolled31 locationsNCT07004972
Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Non-Hodgkin LymphomaMultiple MyelomaChronic Lymphocytic Leukaemia
Bristol-Myers Squibb50 enrolled8 locationsNCT06357754